| Business Summary | | Dendreon
Corporation
discovers
and
develops
immunologically
based
therapeutic
products
for
the
treatment
of
cancer.
The
Company's
lead
product,
Provenge,
is
a
therapeutic
vaccine
for
the
treatment
of
prostate
cancer
and
is
in
Phase
III
clinical
trials,
the
final
stage
of
product
development.
Dendreon
is
conducting
Phase
II
clinical
trials
for
Mylovenge,
its
therapeutic
vaccine
for
the
treatment
of
multiple
myeloma.
The
Company's
vaccine
for
the
treatment
of
breast,
ovarian
and
colon
cancer,
APC8024,
was
cleared
by
the
Food
and
Drug
Administration
to
begin
Phase
I
clinical
trials
at
the
end
of
2000.
The
Company
has
additional
therapeutic
vaccines
in
preclinical
development
for
the
treatment
of
common
malignancies,
including
lung,
bladder
and
uterine
cancers. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Dendreon
Corp.
is
engaged
in
the
research
and
development
of
immunologically-based
therapeutic
products
for
the
treatment
of
cancer.
The
Company
develops
vaccines
that
stimulate
cancer-fighting
cells.
For
the
six
months
ended
6/30/01,
total
revenues
rose
from
$2.3
million
to
$6.2
million.
Net
loss
applicable
to
Common
fell
31%
to
$8.3
million.
Revenues
reflect
agreements
with
R.W.
Johnson.
Lower
loss
reflects
higher
interest
income
due
to
higher
average
cash
balances. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Christopher Henney, Ph.D., 60 Chairman,
CEO | $615K | $2.0M | David Urdal, Ph.D., 51 Vice
Chairman, Pres and CSO | 450K | 663K | Martin Simonetti, 43 CFO,
Sr. VP-Fin., Treasurer | 290K | 225K | T. Dennis George, 62 Sr.
VP- Corp. Affairs, Gen. Counsel, Sec. | 245K | -- | Frank Valone, M.D., 51 Sr.
VP, Medical and Regulatory Affairs and CMO | 330K | 90K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|